Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
about
BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.Examining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamicsPrevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancersBRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.Family history and breast cancer hormone receptor status in a Spanish cohort.Oncogenes and tumor suppressor genesImmunophenotypic predictive profiling of BRCA1-associated breast cancer.Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk.Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review.Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Online tool to guide decisions for BRCA1/2 mutation carriers.BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like siteMechanisms of BRCA1 tumor suppressionNovel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer familiesDNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer.A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.Exploring phenotype patterns of breast cancer within somatic mutations: a modicum in the intrinsic code.Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumours.Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?BRCA1/2 testing: therapeutic implications for breast cancer management
P2860
Q26822737-F53F83CD-475E-4669-BBAB-388396A1BEEAQ27852587-7419201A-3DC1-4522-9CFD-6A342D67D469Q28383242-7F83362D-A396-4189-A464-A532B4918485Q33748161-4EB5B807-7455-4257-AF46-664382CF409EQ33930051-81115E14-4F28-410C-B052-D557C5948DB2Q34097351-7BF77343-B1D2-4D86-BBD8-4524ED631312Q34125091-C4F08C4B-6A13-43C8-B6E9-A0DD53EEAFE2Q34149922-5DEAA39D-3F5C-490C-9C5E-7339DB5284D5Q34467646-87857893-8823-4B62-8539-357E021596B2Q34621039-789BFB15-162C-463B-9FAD-20BFB08C4F6DQ34738030-906AD000-E655-4482-B8BF-788BAA138FD1Q35018746-1068D9B4-B53F-4853-AB96-6AE9A475E4A2Q35155449-07BFEBE9-5A13-4772-BC3B-577E1CC393B5Q35565644-AC88587E-F9C5-41FE-A628-4BD1EF72907EQ35683623-941491A0-7484-48BE-BC4E-1533E073F96EQ35687632-2DCC3F10-5DFD-41AE-AFFF-306B97E2F263Q35737888-4CC767B5-56B8-4F9F-8B27-848A61D5BB54Q35808372-3E0AABEA-C793-4528-950B-E27C24825929Q36072014-EF05972C-F623-4821-BC3F-1A46D841B0F7Q36219554-7696CD56-90AF-4776-844A-5C586673020BQ36642880-B58DBBBA-2936-439B-AE09-7F780B024ADBQ36833424-00288AFF-C625-48AC-8DF0-0ABA865762E4Q37158337-1A3CB1EB-7392-43E4-A623-FBD1B6C2BCE9Q39000667-D047A106-78F3-49BC-BF6F-DA4CF13F1E4AQ39752527-163A61BD-0D7B-4DB3-9927-2A0B8B686CB8Q40903518-DFA334B6-B4CB-4E23-94AA-DEDD4CB76910Q42482668-B28263FB-B24C-4953-95CD-CB3DA5B32FA6Q42501214-6BD89112-88AC-4805-8AE7-916C98885680Q42763529-A65B3C21-FD32-4C6E-BF78-D7F5D3502129Q57110101-1632363A-FB52-4D2A-896B-C42074529D55
P2860
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Estrogen receptor positive bre ...... actors and pathologic features
@ast
Estrogen receptor positive bre ...... actors and pathologic features
@en
type
label
Estrogen receptor positive bre ...... actors and pathologic features
@ast
Estrogen receptor positive bre ...... actors and pathologic features
@en
prefLabel
Estrogen receptor positive bre ...... actors and pathologic features
@ast
Estrogen receptor positive bre ...... actors and pathologic features
@en
P2093
P2860
P356
P1476
Estrogen receptor positive bre ...... actors and pathologic features
@en
P2093
Amy H Comander
Bridget Gallagher
Dennis Sgroi
Jennifer Kaplan
Judy E Garber
Karen Krag
Katharina Fetten
Kathryn A Stoeckert
Laura C Collins
P2860
P2888
P356
10.1186/BCR2478
P577
2010-02-11T00:00:00Z
P5875
P6179
1045817258